Health Effects of Milk Proteins in Elderly Subjects

University of Oslo50 enrolled

Overview

The aim of the present study is to investigate effects of milk on body composition and muscle strength, inflammation, appetite, DNA damage/repair and PBMC whole genome transcriptomics in elderly subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Healthy

Interventions

MilkDIETARY_SUPPLEMENT

4 dl milk will be consumed daily with breakfast and supper for 12 weeks

PlaceboDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 70 years of age * reduced gait speed or * reduced "five times sit to stand test" or * reduced "timed step stair test " or * reduced grip strength * Stable body weight (last 3 months) * Mini Nutritional Assessment (MNA®) score ≥ 17 * Mini-mental status (MMSE-NR) score: ≥ 24 * Willing to participate according to the protocol Exclusion Criteria: * Allergy/intolerance to milk/dairy products * High intake of milk and yoghurt * Physical active subjects * Known diabetes type I or II, or HbA1c ≥ 6,5% * Recent events of acute cardiovascular disease including stroke * Rapidly evolving diseases (active malignancy) or history of cancer (malignant tumors) last 3 years. * Severe inflammation-related diseases such as e.g. Crohn disease and arthritis * Chronic obstructive pulmonary disease * Increased blood pressure * High intake of alcohol * Reduced kidney function (GFR \< 45 ml/min) * Increased hsCRP, ASAT, ALAT * Increased or suppressed TSH * Hormone therapy * Systemic use of glucocorticosteroids (anti-inflammatory steroid hormones). Use of spray and inhalator use is not exclusion. * Disability preventing physical tests * Using medications known to affect protein metabolism

Locations (1)

University of Oslo

Oslo, Post Box 1046, Blindern, Norway

Outcomes

Primary Outcomes

Change in muscle mass, strength and performance

Change in muscle is mass measured by DXA. Muscle strength and performance are measured by several physical tests such as repeated chair stands, handgrip strength, step stair test and strength in legs and torso and gait speed and are considered as the clinical relevant outcomes.

Time frame: Measured at baseline and after 12 weeks (end-of-study visit)

Secondary Outcomes

Changes in levels of inflammatory markers

Changes in levels of inflammatory markers in circulation and at PBMC gene Expression Level such as i.e. CRP, IL-6, TNFa, IL-8, IL-18, ICAM, VCAM.

Time frame: Measured at baseline and after 12 weeks (end-of-study visit)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.